Anti-HIV drugs decrease the expression of matrix metalloproteinases in astrocytes and microglia

Brain

Volumn 127, Issue 2, 2004, Pages 398-407

  Liuzzi, Grazia Maria ^a   Mastroianni, C M ^b   Latronico, T ^a   Mengoni, F ^b   Fasano, A ^a   Lichtner, M ^b   Vullo, V ^b   Riccio, P ^c  

^a UNIVERSITY OF BARI   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c UNIVERSITY OF BASILICATA   (Italy)

Author keywords

Antiretroviral drugs; Astrocytes; HIV dementia; Matrix metalloproteinases; Microglia

Indexed keywords

ANTIRETROVIRUS AGENT; GELATINASE A; GELATINASE B; INDINAVIR; LIPOPOLYSACCHARIDE; MATRIX METALLOPROTEINASE; MESSENGER RNA; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; ZIDOVUDINE;

ANIMAL CELL; ANTIVIRAL ACTIVITY; ARTICLE; ASTROCYTE; CONTROLLED STUDY; DEMENTIA; DOSE RESPONSE; ENZYME ACTIVITY; GLIA CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MICROGLIA; NERVE CELL CULTURE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT;

ANIMALS; ANTI-HIV AGENTS; ASTROCYTES; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; GENE EXPRESSION REGULATION, ENZYMOLOGIC; INDINAVIR; LIPOPOLYSACCHARIDES; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MATRIX METALLOPROTEINASES; MICROGLIA; RATS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; ZIDOVUDINE;

EID: 0742305822     PISSN: 00068950     EISSN: None     Source Type: Journal    
DOI: 10.1093/brain/awh049     Document Type: Article

References (55)

1. Brown PD. Ongoing trials with matrix metalloproteinase inhibitors. Expert Opin Investig Drugs 2000; 9: 2167-77.
2. Burger DM, Kraaijeveld CL, Meenhorst PL, Mulder JW, Koks CH, Bult A, et al. Penetration of zidovudine into the cerebrospinal fluid of patients infected with HIV. AIDS 1993; 7: 1581-7.
3. Conant K, Garzino-Demo A, Nath A, McArthur JC, Halliday W, Power C, et al. Induction of monocyte chemoattractant protein-1 in HIV-1 Tat-stimulated astrocytes and elevation in AIDS dementia. Proc Natl Acad Sci USA 1998; 95: 3117-21.
4. Conant K, McArthur JC, Griffin DE, Sjulson L, Wahl LM, Irani DN. Cerebrospinal fluid levels of MMP-2, 7, and 9 are elevated in association with human immunodeficiency virus dementia. Ann Neurol 1999; 46: 391-8.
5. Cuzner ML, Gveric D, Strand C, Loughlin AJ, Paemen L, Opdenakker G, et al. The expression of tissue-type plasminogen activator, matrix metalloproteases and endogenous inhibitors in the central nervous system in multiple sclerosis: comparison of stages in lesion evolution. J Neuropathol Exp Neurol 1996; 55: 1194-204.
6. Dal Canto MC. AIDS and the nervous system: current status and future perspectives. [Review]. Hum Pathol 1989; 20: 410-8.
7. Dhawan S, Toro LA, Jones BE, Meltzer MS. Interactions between HIV-infected monocytes and the extracellular matrix: HIV-infected monocytes secrete neutral metalloproteases that degrade basement membrane protein matrices. J Leukoc Biol 1992; 52: 244-8.
8. Enting RH, Hoetelmans RM, Lange JM, Burger DM, Beijnen JH, Portegies P. Antiretroviral drugs and the central nervous system. [Review]. AIDS 1998; 12: 1941-55.
9. Estaquier J, Lelievre JD, Petit F, Brunner T, Moutouh-De Parseval L, Richman DD, et al. Effect of antiretroviral drugs on human immunodeficiency virus type 1-induced CD4+ T-cell death. J Virol 2002; 76: 5966-73.
10. Gearing AJ, Beckett P, Christodoulou M, Churchill M, Clements J, Davidson AH, et al. Processing of tumor necrosis factor-α precursor by metalloproteinases. Nature 1994; 370: 555-7.
11. Gebicke-Haerter PJ, Bauer J, Schobert A, Northoff H. Lipopolysaccharide-free conditions in primary astrocyte cultures allow growth and isolation of microglial cells. J Neurosci 1989; 9: 183-94.
12. Gendelman HE, Persidsky Y, Ghorpade A, Limoges J, Stins M, Fiala M, et al. The neuropathogenesis of the AIDS dementia complex. [Review]. AIDS 1997; 11 Suppl A: S35-45.
13. Gomez DE, Alonso DF, Yoshiji H, Thorgeirsson UP. Tissue inhibitors of metalloproteinases: structure, regulation and biological functions. [Review]. Eur J Cell Biol 1997; 74: 111-22.
14. Gottschall PE, Yu X. Cytokines regulate gelatinase A and B (matrix metalloproteinase 2 and 9) activity in cultured rat astrocytes. J Neurochem 1995a; 64: 1513-20.
15. Gottschall PE, Yu X, Bing B. Increased production of gelatinase B (matrix metalloproteinase-9) and interleukin-6 by activated rat microglia in culture. J Neurosci Res 1995b; 42: 335-42.
16. Hartung HP, Kieseier BC. The role of matrix metalloproteinases in autoimmune damage to the central and peripheral nervous system. [Review]. J Neuroimmunol 2000; 107: 140-7.
17. Heussen C, Dowdle EB. Electrophoretic analysis of plasminogen activators in polyacrylamide gels containing sodium dodecyl sulfate and copolymerized substrates. Anal Biochem 1980; 102: 196-202.
18. Janabi N, Di Stefano M, Wallon C, Hery C, Chiodi F, Tardieu M. Induction of human immunodeficiency virus type 1 replication in human glial cells after proinflammatory cytokines stimulation: effect of IFN-γ, IL1-β, and TNF-α on differentiation and chemokine production in glial cells. Glia 1998; 23: 304-15.
19. Johnston JB, Zhang K, Silva C, Shalinsky DR, Conant K, Ni W, et al. HIV-1 Tat neurotoxicity is prevented by matrix metalloproteinase inhibitors. Ann Neurol 2001; 49: 230-41.
20. Kaufmann D, Pantaleo G, Sudre P, Telenti A. CD4-cell count in HIV-1-infected individuals remaining viraemic with highly active antiretroviral therapy (HAART). Lancet 1998; 351: 723-4.
21. Kieseier BC, Seifert T, Giovannoni G, Hartung HP. Matrix metalloproteinases in inflammatory demyelination: targets for treatment. [Review]. Neurology 1999; 53: 20-5.
22. Levitz SM. Improvement in CD4+ cell counts despite persistently detectable HIV load. New Engl J Med 1998; 338: 1074-5.
23. Liuzzi GM, Mastroianni CM, Vullo V, Jirillo E, Delia S, Riccio P. Cerebrospinal fluid myelin basic protein as predictive marker of demyelination in AIDS dementia complex. J Neuroimmunol 1992; 36: 251-4.
24. Liuzzi GM, Mastroianni CM, Fanelli M, Massetti AP, Vullo V, Delia S, et al. Myelin degrading activity in the CSF of HIV-1-infected patients with neurological diseases. Neuroreport 1994; 6: 157-60.
25. Liuzzi GM, Santacroce MP, Peumans WJ, Van Damme EJM, Dubois B, Opdenakker G, et al. Regulation of gelatinases in microglia and astrocyte cell cultures by plant lectins. Glia 1999; 27: 53-61.
26. Liuzzi GM, Mastroianni CM, Santacroce MP, Fanelli M, D'Agostino C, Vullo V, et al. Increased activity of matrix metalloproteinases in the cerebrospinal fluid of patients with HIV-associated neurological diseases. J Neurovirol 2000; 6: 156-63.
27. Liuzzi GM, Trojano M, Fanelli M, Avolio C, Fasano A, Livrea P, et al. Intrathecal synthesis of matrix metalloproteinase-9 in patients with multiple sclerosis: implication for pathogenesis. Mult Scler 2002; 8: 222-8.
28. Maeda A, Sobel RA. Matrix metalloproteinases in the normal human central nervous system, microglial nodules, and multiple sclerosis lesions. J Neuropathol Exp Neurol 1996; 55: 300-9.
29. Martin C, Sonnerborg A, Svensson JO, Stahle L. Indinavir-based treatment of HIV-1 infected patients: efficacy in the central nervous system. AIDS 1999; 13: 1227-32.
30. Mastroianni CM, Liuzzi GM, Vullo V, Jirillo E, Delia S, Riccio P. Detection of cerebrospinal fluid antibodies against myelin basic protein in patients with AIDS dementia complex. Mol Chem Neuropathol 1991; 14: 227-36.
31. Mastroianni CM, Liuzzi GM, Vullo V, Delia S, Riccio P. Cerebrospinal fluid myelin basic protein in AIDS dementia complex: relationship to disease progression and zidovudine treatment. AIDS 1992; 6: 1214-5.
32. Mastroianni CM, Liuzzi GM, D'Ettorre G, Lichtner M, Forcina G, Di Campli NF, et al. Matrix metalloproteinase-9 and tissue inhibitors of matrix metalloproteinase-1 in plasma of patients co-infected with HCV and HIV. HIV Clin Trials 2002; 3: 310-5.
33. McCarthy KD, De Vellis J. Preparation of separate astroglial and oligodendroglial cell cultures from rat cerebral tissue. J Cell Biol 1980; 85: 890-902.
34. Mezzaroma I, Carlesimo M, Pinter E, Muratori DS, Di Sora F, Chiarotti F, et al. Clinical and immunologic response without decrease in virus load in patients with AIDS after 24 months of highly active antiretroviral therapy. Clin Infect Dis 1999; 29: 1423-30.
35. Monini P, Sgadari C, Barillari G, Ensoli B. HIV protease inhibitors: antiretroviral agents with anti-inflammatory, anti-angiogenic and anti-tumour activity. J Antimicrob Chemother 2003; 51: 207-11.
36. Mooser V, Carr A. Antiretroviral therapy-associated hyperlipidaemia in HIV disease. [Review]. Curr Opin Lipidol 2001; 12: 313-9.
37. Nakajima K, Hamanoue M, Shimojo M, Takei N, Kohsaka S. Characterization of microglia isolated from a primary culture of embryonic rat brain by a simplified method. Biomed Res 1989; 10: 411-23.
38. Nottet HS. Interactions between macrophages and brain microvascular endothelial cells: role in pathogenesis of HIV-1 infection and blood-brain barrier function. [Review]. J Neurovirol 1999; 5: 659-69.
39. Opdenakker G, Van Damme J. Cytokine-regulated proteases in autoimmune diseases. [Review]. Immunol Today 1994; 15: 103-7.
40. Pavlaki M, Zucker S. Matrix metalloproteinase inhibitors (MMPIs): the beginning of phase I or the termination of phase III clinical trials. Cancer Metastasis Rev 2003; 22: 177-203.
41. Phenix BN, Lum JJ, Nie Z, Sanchez-Dardon J, Badley AD. Antiapoptotic mechanism of HIV protease inhibitors: preventing mitochondrial transmembrane potential loss. Blood 2001; 98: 1078-85.
42. Phenix BN, Cooper C, Owen C, Badley AD. Modulation of apoptosis by HIV protease inhibitors. [Review]. Apoptosis 2002; 7: 295-312.
43. Price RW. Neurological complication of HIV infection. [Review]. Lancet 1996; 348: 445-52.
44. Proost P, Van Damme J, Opdenakker G. Leukocyte gelatinase B cleavage releases encephalitogens from human myelin basic protein. Biochem Biophys Res Commun 1993; 192: 1175-81.
45. Romanic AM, Madri JA The induction of 72-kD gelatinase in T cells upon adhesion to endothelial cells is VCAM-1 dependent. J Cell Biol 1994; 125: 1165-78.
46. Sacktor N, Lyles RH, Skolasky R, Kleeberger C, Selnes OA, Miller EN, et al. HIV-associated neurologic disease: incidence changes. Multicenter AIDS Cohort Study, 1990-1998. Neurology 2001; 56: 257-60.
47. Shapiro SD. Matrix metalloproteinase degradation of extracellular matrix: biological consequences. [Review]. Curr Opin Cell Biol 1998; 10: 602-8.
48. Sporer B, Paul R, Koedel U, Grimm R, Wick M, Goebel FD, et al. Presence of matrix metalloproteinase-9 activity in the cerebrospinal fluid of human immunodeficiency virus-infected patients. J Infect Dis 1998; 178: 854-7.
49. Sporer B, Koedel U, Paul R, Kohleisen B, Erfle V, Fontana A, et al. Human immunodeficiency virus type-1 Nef protein induces blood-brain barrier disruption in the rat: role of matrix metalloproteinase-9. J Neuroimmunol 2000; 102: 125-30.
50. Stahle L, Martin C, Svensson JO, Sonnerborg A. Indinavir in cerebrospinal fluid of HIV-1-infected patients. Lancet 1997; 350: 1823.
51. Suryadevara R, Holter S, Borgmann K, Persidsky R, Labenz-Zink C, Persidsky Y, et al. Regulation of tissue inhibitor of metalloproteinase-1 by astrocytes: links to HIV-1 dementia. Glia 2003; 44: 47-56.
52. Weeks BS. The role of HIV-1 activated leukocytes adhesion mechanisms and matrix metalloproteinases secretion in AIDS pathogenesis. Int J Mol Med 1997; 1: 361-6.
53. Whittaker M, Floyd CD, Brown P, Gearing AJ. Design and therapeutic application of matrix metalloproteinase inhibitors. Chem Rev 1999; 99: 2735-76.
54. Woessner JF Jr. Matrix metalloproteinases and their inhibitors in connective tissue remodelling. [Review]. FASEB J 1991; 5: 2145-54.
55. Yong VW, Krekoski CA, Forsyth PA, Bell R, Edwards DR. Matrix metalloproteinases and diseases of the CNS. [Review]. Trends Neurosci 1998; 21: 75-80.